Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.

Abstract

Development of a vaccine against Epstein-Barr virus (EBV) is constrained by the latency phenotypes adopted by different EBV-associated diseases. Over the last few years an immense body of information on the pattern of viral gene expression in EBV-associated diseases and the role of cytotoxic T cells in the control of these diseases has accumulated. It would seem reasonable to suggest that emerging technologies are at a level where vaccine trials aimed at controlling infectious mononucleosis, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma and Hodgkin's disease are justified. On the other hand, a more cautious approach may be required for the development of vaccines or immunotherapeutic strategies against Burkitt's lymphoma.

• Authors: R Khanna, D J Moss, S R Burrows
• Journal: Immunological reviews (Immunol Rev) Vol. 170 Pg. 49-64 (Aug 1999) ISSN: 0105-2896 [Print] England
• PMID: 10566141 (Publication Type: Journal Article, Review)

Chemical References

• Antigens, Viral
• Viral Vaccines

Topics

• Animals
• Antigens, Viral
• Burkitt Lymphoma (immunology, therapy)
• Disease Models, Animal
• Epstein-Barr Virus Infections (immunology, prevention & control, virology)
• Herpesvirus 4, Human (genetics, immunology, pathogenicity)
• Humans
• Immunotherapy
• Infant, Newborn
• Infectious Mononucleosis (immunology, prevention & control)
• Mice
• Phenotype
• Primates
• T-Lymphocytes, Cytotoxic (immunology)
• Viral Vaccines (pharmacology)